Investigational drug · Phase 3
GZR4
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
13
Any phase or sponsor naming "GZR4"
First trial start
2025
Feb 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GZR4", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetes
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "GZR4" as an intervention, largest first.
- A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinPivotal-lookingActive, not recruiting
Gan & Lee Pharmaceuticals.Industry
NCT06767748 · 620 participants (planned) · Start Feb 15, 2025 · Primary completion Feb 7, 2026
Drug: GZR4; insulin degludec · For: Diabetes
Sites: Linyi, China
- A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial InsulinPivotal-lookingActive, not recruiting
Gan & Lee Pharmaceuticals.Industry
NCT06767761 · 580 participants (planned) · Start Feb 18, 2025 · Primary completion Mar 19, 2026
Drug: GZR4; Insulin Glargine U100 group · For: Diabetes
Sites: Changsha, China
- A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)Pivotal-lookingActive, not recruiting
Gan & Lee Pharmaceuticals.Industry
NCT06767735 · 580 participants (planned) · Start Feb 17, 2025 · Primary completion Aug 1, 2026
Drug: GZR4; Insulin Glargine U100 · For: Diabetes
Sites: Linyi, China
- A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinPivotal-lookingRecruiting
Gan & Lee Pharmaceuticals.Industry
NCT07165223 · 300 participants (planned) · Start Oct 17, 2025 · Primary completion Nov 10, 2026
Drug: GZR4; Insulin Icodec group · For: Diabetes
Sites: Linyi, China
- A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes MellitusPivotal-lookingCompleted
Gan and Lee Pharmaceuticals, USAIndustry
NCT06202079 · 179 participants · Start Aug 11, 2023 · Primary completion Jul 13, 2024
Drug: GZR4 Injection; Insulin Degludec · For: Diabetes Mellitus, Type 2
Sites: Wuhan, China; Changzhou, China; Jinan, China · 8 sites in all
- Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult ParticipantsNot yet recruiting
Gan & Lee Pharmaceuticals.Industry
NCT07670897 · 64 participants (planned) · Start Jul 1, 2026 · Primary completion Jul 29, 2026
Drug: GZR4 injection A; GZR4 injection B · For: T2D
Sites: Linyi, China
Gan and Lee Pharmaceuticals, USAIndustry
NCT06548815 · 43 participants · Start Aug 29, 2022 · Primary completion Mar 24, 2023
Drug: GZR4; Placebo · For: Diabetes
Sites: Beijing, China
- Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic ImpairmentActive, not recruiting
Gan & Lee Pharmaceuticals.Industry
NCT07193147 · 36 participants (planned) · Start Oct 20, 2025 · Primary completion Jul 14, 2026
Drug: GZR4 · For: Diabetes
Sites: Linyi, China
Gan and Lee Pharmaceuticals, USAIndustry
NCT06553248 · 36 participants · Start Mar 22, 2023 · Primary completion Nov 1, 2023
Drug: GZR4; Insulin Degludec · For: Diabetes
Sites: Beijing, China
Gan & Lee Pharmaceuticals.Industry
NCT06974487 · 30 participants (planned) · Start May 8, 2025 · Primary completion Sep 30, 2025
Drug: GZR102 injection; GZR4 injection and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial.
Chen L, Dong X, Zhang Q, et al. · Metabolism 2026
- Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants.
Liu L, Dong J, Tong Y, et al. · Diabetes Obes Metab 2026
- A phase 1b, randomized, open-label study of once-weekly insulin GZR4 in patients with type 2 diabetes mellitus.
Wang X, Hu Y, Tang C, et al. · Diabetes Res Clin Pract 2026
- Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trial.
Liu H, Yu Y · Diabetes Obes Metab 2025
- Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trial.
Tang C, Su R, Wan L, et al. · Diabetes Obes Metab 2025
Also in development for Diabetes
- Dihuang Baoyuan Granulesprescription BPhase 23 trials
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. · Diabetes Mellitus, Type 2, Diabetes, Type2diabetes
- Fuling Yunhua Granulesprescription APhase 23 trials
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. · Diabetes Mellitus, Type 2, Diabetes, Type2diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.